Participated in Sidewinder Therapeutics' $137M Series B financing to advance next-generation bispecific ADCs for cancer.
APR 8, 2026
Sidewinder Therapeutics is pioneering the next generation of bispecific antibody-drug conjugates (ADCs) that expand the therapeutic window for patients with difficult to treat cancers
Sidewinder Therapeutics is pioneering the next generation of bispecific antibody-drug conjugates (ADCs) that expand the therapeutic window for patients with difficult to treat cancers. The company is advancing bispecific ADCs engineered to target receptor co-complexes that are highly expressed on certain solid tumors with enhanced tumor cell specificity and internalization.